HGEN
Humanigen Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
kalobios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. our mission is to improve the lives of cancer patients with innovative, humaneered®, monoclonal antibodies. kalobios' humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products. using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. our pipeline is comprised of humaneered® antibodies. these antibodies are being investigated in clinical development programs focused on treating cancer: kb004 (anti-epha3) humaneered® mab to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s phase 2 expansion portion of its phase 1/2 clinical trial in hematologic malignancies; and kb003 (anti-gm-csf) humaneered® mab that kal
Market Cap: 22.8 Million
Primary Exchange: NASDAQ
Website: https://www.humanigen.com/
Shares Outstanding: 119 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0565873251991904
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 813 trading days
From: 2021-02-19 To: 2023-07-25
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|